Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified Buzhong Yiqi Decoction is a Traditional Chinese Medicine (TCM) herbal formulation derived from the classic Buzhong Yiqi Decoction, specifically adapted for the treatment of benign prostatic hyperplasia (BPH) and detrusor hypofunction (underactive bladder). Developed and utilized by clinicians at Fangcun Hospital (a branch of the Guangdong Provincial Hospital of Traditional Chinese Medicine), the formula is designed to address the TCM pattern of "Spleen-Qi deficiency" and "sunken Yang," which are thought to contribute to poor bladder contractility and urinary retention. The modification typically involves the addition of specific herbs that promote diuresis and improve the myogenic tone of the detrusor muscle. It is frequently employed as a post-operative recovery aid for patients undergoing transurethral resection of the prostate (TURP) who continue to experience voiding dysfunction due to detrusor underactivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified buzhong yiqi decoction.